{"filing":{"accession_number":"0001213900-26-070884","cik":"0001614744","ticker":"PPBT","company_name":"PURPLE BIOTECH LTD.","form":"6-K","filing_date":"2026-06-23","report_date":null,"primary_document":"ea0295622-6k_purple.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1614744/000121390026070884/ea0295622-6k_purple.htm"},"events":[{"id":13060,"run_id":11587,"accession_number":"0001213900-26-070884","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This is a corporate presentation disclosing Purple Biotech's CAPTN-3 tri-specific antibody platform and pipeline progress, including preclinical data for lead program IM1240 and second program IM1305, with planned IND submission in 2027 and Phase 1 initiation in H1 2027. The presentation details the company's technology, mechanism of action, and development roadmap for immuno-oncology candidates. While this is a strategic/operational disclosure of product development milestones and platform capabilities rather than a discrete event like M\u0026A or earnings, it represents material progress on the company's core pipeline and would affect a reasonable investor's assessment of the registrant's development trajectory and value creation potential.","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-06-23","form":"6-K","submitted_at":null,"items":[{"id":10097,"accession_number":"0001213900-26-070884","item_number":"EX-99.1","item_title":"ea029562201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is a corporate presentation disclosing Purple Biotech's CAPTN-3 tri-specific antibody platform and pipeline progress, including preclinical data for lead program IM1240 and second program IM1305, with planned IND submission in 2027 and Phase 1 initiation in H1 2027. The presentation details the company's technology, mechanism of action, and development roadmap for immuno-oncology candidates. While this is a strategic/operational disclosure of product development milestones and platform capabilities rather than a discrete event like M\u0026A or earnings, it represents material progress on the company's core pipeline and would affect a reasonable investor's assessment of the registrant's development trajectory and value creation potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T13:29:38.287904+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10097,"accession_number":"0001213900-26-070884","item_number":"EX-99.1","item_title":"ea029562201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is a corporate presentation disclosing Purple Biotech's CAPTN-3 tri-specific antibody platform and pipeline progress, including preclinical data for lead program IM1240 and second program IM1305, with planned IND submission in 2027 and Phase 1 initiation in H1 2027. The presentation details the company's technology, mechanism of action, and development roadmap for immuno-oncology candidates. While this is a strategic/operational disclosure of product development milestones and platform capabilities rather than a discrete event like M\u0026A or earnings, it represents material progress on the company's core pipeline and would affect a reasonable investor's assessment of the registrant's development trajectory and value creation potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T13:29:38.287904+00:00","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-06-23"}]}